SCHEMBL13733627

SCHEMBL13733627

CC(C)CC1CN(C(=O)OC(C)(C)C)C(=O)N1C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 2/20 0.35
KLK5 Q9Y337 1/20 0.35
NR1H2 P55055 1/20 0.35
MMP3 P08254 1/20 0.33
ADAM17 P78536 1/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
THRB P10828 1/20 0.33
TACR1 P25103 2/20 0.32
USP30 Q70CQ3 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
RAB9A P51151 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PLA2G10 O15496 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13732339 0.82 ATM (0.39) KLK7KLK5NR1H2MAPTKDM4E
SCHEMBL3398097 0.80 CHRM2 (0.37) KLK7KLK5NR1H2MMP3ADAM17
SCHEMBL13731951 0.78 NR1H2 (0.33) KLK7KLK5NR1H2MAPTKDM4E
SCHEMBL581822 0.75 CHRM2 (0.34) KLK7KLK5NR1H2MMP3ADAM17
SCHEMBL5573878 0.73 MAPT (0.40) MMP3ADAM17MAPTKDM4ETHRB
SCHEMBL5573872 0.73 MAPT (0.40) MMP3ADAM17MAPTKDM4ETHRB
SCHEMBL24364010 0.72 NR1H2 (0.35) KLK7KLK5NR1H2MMP3ADAM17
SCHEMBL4774639 0.72 MME (0.38) KLK7KLK5NR1H2MMP3ADAM17
SCHEMBL8021097 0.71 CHRM2 (0.42) KLK7KLK5NR1H2MMP3ADAM17
SCHEMBL29060412 0.71 MMP3 (0.37) NR1H2MMP3ADAM17MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2699581-B1 2-OXO-1-IMIDAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2015-11-25 EP disclosed
US-8957218-B2 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives UCB PHARMA S.A. (BE) 2015-02-17 US disclosed
US-20140148489-A1 2-Oxo-1-Imidazolidinyl Imidazothiadiazole Derivatives UCB PHARMA, S.A. (BE) 2014-05-29 US disclosed
EP-2699581-A1 2-OXO-1-IMIDAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB Pharma, S.A. (BE) 2014-02-26 EP disclosed
WO-2012143117-A1 2-OXO-1-IMIDAZOLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB PHARMA, S.A. (BE) 2012-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148489-A1 2-Oxo-1-Imidazolidinyl Imidazothiadiazole Derivatives CYP3A4, CYP3A43, CYP3A7 KLK7 3304/4885KLK5 2339/4885NR1H2 3482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.